Cardiogenics Holding (CGNH) 0.0266 $CGNH
USPTO Issues Notice of Allowance in Connection With CardioGenics' Self-Metering Cartridge Patent Application
GlobeNewswire - Tue Feb 17, 8:50AM CST
CardioGenics Holdings Inc. (OTCQB:CGNH), developer of the ultra-sensitive QL Care(TM) analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics ("IVD"
testing market, announced today that the United States Patent & Trademark Office ("USPTO" has issued a Notice of Allowance with respect to certain patent claims contained in its patent application for the self-metering cartridge to be utilized in the Company's QL Care(TM) analyzer. The Notice of Allowance, which is the USPTO's notice to the Company that the allowed patent claims are entitled to patent protection, now clears the way for the issuance of the patent for the self-metering cartridge, upon payment of the applicable patent issuance fees.
InsiderInsights.com Daily Round Up 2/11/15: GRUB, FSC, RENT, SXC
InsiderInsights - at Seeking Alpha - Thu Feb 12, 11:02AM CST
GRA: 99.50 (-0.08), GRUB: 43.81 (-0.10), SXC: 15.68 (+0.18), RENT: 53.31 (+0.61), ASPX: 100.58 (+0.10), BH: 411.19 (-13.71), NOW: 82.34 (+0.60), FSC: 7.09 (-0.07), NWL: 40.04 (+0.05), AST: 8.27 (+0.28), AVNU: 12.28 (-0.08), WDR: 47.94 (-1.12), DATA: 97.22 (+0.46), CRM: 67.64 (-0.10)
CardioGenics Announces Appointment of New Director
GlobeNewswire - Mon Jan 12, 3:30PM CST
CardioGenics Holdings Inc. (OTCQB:CGNH), developer of the ultra-sensitive QL Care(TM) analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics testing market, announced today that Karim Murabet has been appointed as a director of the Company, effective January 12, 2015. Mr. Murabet will serve as an independent director.
CORRECTING AND REPLACING -- CardioGenics Announces $1.3 Million Private Placement to European Investors
GlobeNewswire - Thu Jun 12, 4:00PM CDT
Please replace the release with the following corrected version due to an incorrect date in the last paragraph of the release, which should read "... late July 2014" instead of "... late July 2013."
CardioGenics Announces $1.3 Million Private Placement to European Investors
GlobeNewswire - Thu Jun 12, 9:04AM CDT
CardioGenics Holdings Inc. (OTCBB:CGNH), developer of the QL Care(TM) analyzer, an ultra-sensitive immunoassay point-of-care analyzer, and other products targeting the In-Vitro Diagnostics testing market, today announced it has sold $1.3 million of its common stock in a private placement to European institutional and other investors. Closing of the transaction is subject to listing of the shares on the NewConnect Market of the Warsaw Stock Exchange. WDM acted as offering agent and leading financial advisor on the transaction.
USPTO Issues Notice of Allowance in Connection With CardioGenics' Self-Metering Cartridge Patent Application
GlobeNewswire - Tue Feb 17, 8:50AM CST
CardioGenics Holdings Inc. (OTCQB:CGNH), developer of the ultra-sensitive QL Care(TM) analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics ("IVD"
testing market, announced today that the United States Patent & Trademark Office ("USPTO" has issued a Notice of Allowance with respect to certain patent claims contained in its patent application for the self-metering cartridge to be utilized in the Company's QL Care(TM) analyzer. The Notice of Allowance, which is the USPTO's notice to the Company that the allowed patent claims are entitled to patent protection, now clears the way for the issuance of the patent for the self-metering cartridge, upon payment of the applicable patent issuance fees. InsiderInsights.com Daily Round Up 2/11/15: GRUB, FSC, RENT, SXC
InsiderInsights - at Seeking Alpha - Thu Feb 12, 11:02AM CST
GRA: 99.50 (-0.08), GRUB: 43.81 (-0.10), SXC: 15.68 (+0.18), RENT: 53.31 (+0.61), ASPX: 100.58 (+0.10), BH: 411.19 (-13.71), NOW: 82.34 (+0.60), FSC: 7.09 (-0.07), NWL: 40.04 (+0.05), AST: 8.27 (+0.28), AVNU: 12.28 (-0.08), WDR: 47.94 (-1.12), DATA: 97.22 (+0.46), CRM: 67.64 (-0.10)
CardioGenics Announces Appointment of New Director
GlobeNewswire - Mon Jan 12, 3:30PM CST
CardioGenics Holdings Inc. (OTCQB:CGNH), developer of the ultra-sensitive QL Care(TM) analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics testing market, announced today that Karim Murabet has been appointed as a director of the Company, effective January 12, 2015. Mr. Murabet will serve as an independent director.
CORRECTING AND REPLACING -- CardioGenics Announces $1.3 Million Private Placement to European Investors
GlobeNewswire - Thu Jun 12, 4:00PM CDT
Please replace the release with the following corrected version due to an incorrect date in the last paragraph of the release, which should read "... late July 2014" instead of "... late July 2013."
CardioGenics Announces $1.3 Million Private Placement to European Investors
GlobeNewswire - Thu Jun 12, 9:04AM CDT
CardioGenics Holdings Inc. (OTCBB:CGNH), developer of the QL Care(TM) analyzer, an ultra-sensitive immunoassay point-of-care analyzer, and other products targeting the In-Vitro Diagnostics testing market, today announced it has sold $1.3 million of its common stock in a private placement to European institutional and other investors. Closing of the transaction is subject to listing of the shares on the NewConnect Market of the Warsaw Stock Exchange. WDM acted as offering agent and leading financial advisor on the transaction.
